Core Viewpoint - Qiming Medical has made significant progress in the European market with its Cardiovalve transcatheter tricuspid valve replacement system, having submitted all application materials for CE certification, marking a key step in market entry [1] Group 1: Stock Performance - Qiming Medical's stock rose over 7% during trading, with a current increase of 4.05%, priced at HKD 2.57, and a trading volume of HKD 4.8942 million [1] Group 2: Product Development - The Cardiovalve system has successfully completed a confirmatory clinical study involving 150 patients in Europe, with positive mid-term results presented at the London Heart Valve Intervention Meeting [1] - The positive data from the TARGET study has received recognition and praise from overseas research expert teams, indicating strong support for the product [1] Group 3: Strategic Positioning - The progression to CE certification for the Cardiovalve system enhances Qiming Medical's "four-valve integration" product strategy, further completing its treatment matrix for tricuspid valve therapy alongside its established aortic and pulmonary valve product lines [1]
启明医疗-B盘中涨超7% Cardiovalve系统正式递交欧洲CE MDR认证申请